SXL
NVS icon

Summit X LLC’s Novartis NVS Stock Holding History

Summit X LLC’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,344
Closed -$237K – 248
2023
Q2 		$237K Buy
2,344
+86
+4% +$8.6K 0.06% 242
2023
Q1 		$208K Sell
2,258
-137
-6% -$12K 0.05% 242
2022
Q4 		$203K Buy
+2,395
New +$202K 0.06% 229
2022
Q3 		– Sell
-2,396
Closed -$204K – 258
2022
Q2 		$204K Buy
2,396
+22
+0.9% +$1.93K 0.06% 229
2022
Q1 		$210K Buy
2,374
+101
+4% +$8.74K 0.05% 238
2021
Q4 		$200K Buy
+2,273
New +$189K 0.05% 247
2021
Q3 		– Sell
-2,307
Closed -$209K – 268
2021
Q2 		$209K Sell
2,307
-94
-4% -$8.37K 0.05% 245
2021
Q1 		$208K Buy
2,401
+9
+0.4% +$808 0.06% 246
2020
Q4 		$226K Sell
2,392
-123
-5% -$10.7K 0.07% 227
2020
Q3 		$2.78K Buy
2,515
+50
+2% +$4.33K 0.05% 164
2020
Q2 		$215K Buy
+2,465
New +$213K 0.08% 190

Other funds holding NVS

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Summit X LLC's NVS Position: Q3 2023 in Review

Summit X LLC sold out of Novartis (NVS) in Q3 2023, closing a stake of 2,344 shares — an estimated $237K sold.

Summit X LLC first reported a position in NVS in Q2 2020 and held it in 11 quarters. The position peaked at $237K in Q2 2023. 1,223 funds tracked by Wall St. Rank hold NVS as of Q3 2023.

  • Summit X LLC reported no remaining Novartis position as of Q3 2023 after selling out during the quarter.
  • Summit X LLC sold 2,344 Novartis shares in Q3 2023, an estimated $237K.
  • Summit X LLC first reported a position in Novartis in Q2 2020 and held it in 11 quarters.
  • Summit X LLC's Novartis position peaked at $237K in Q2 2023.
  • 1,223 funds tracked by Wall St. Rank held Novartis as of Q3 2023.

Based on Summit X LLC's 13F filing for Q3 2023, filed 6 Nov 2023.